Progenics: AACR 2014 Meeting (Progenics) - Apr 11, 2014 - "Clinical results for PSMA ADC"; "Phase 1 and 2 studies in advanced metastatic castration-resistant prostate cancer: Taxane-refractory patients with significant prior exposure to abiraterone and/or enzalutamide"; "Tolerability: Generally well tolerated at 2.3 mg/kg q3 weeks"; "Activity: Reductions in prostate-specific antigen (PSA) and circulating tumor cells (CTC)"; "Conclusion: Clinical proof of concept in a difficult-to-treat patient population"
P2 data • Oncology • Prostate Cancer
|